Take Solutions Ltd — Investor Relations & Filings
Take Solutions Ltd provides specialized domain-led technology and services, primarily focusing on the Life Sciences sector. Through its key brand, Navitas Life Sciences, the company delivers end-to-end solutions across clinical research, regulatory affairs, and pharmacovigilance. Its service offerings include clinical data management, medical writing, and trial monitoring, leveraging proprietary platforms to enhance operational efficiency. The organization supports pharmaceutical, biotechnology, and medical device companies in managing complex regulatory requirements and streamlining the drug development process. By combining deep functional expertise with digital transformation capabilities, Take Solutions facilitates data-driven decision-making and ensures compliance with global safety standards. Its portfolio encompasses strategic consulting and technology-enabled services designed to optimize clinical trial outcomes and accelerate time-to-market for new therapies.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Press Release | 2026-04-17 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-13 | English | |
| Press Release | 2026-04-06 | English | |
| Change in Auditors | 2026-03-26 | English | |
| Outcome of Board Meeting | 2026-03-26 | English | |
| Resignation | 2026-03-25 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42209881 | Press Release | 2026-04-17 | English | ||
| 42189767 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-13 | English | ||
| 42213664 | Press Release | 2026-04-06 | English | ||
| 42163155 | Change in Auditors | 2026-03-26 | English | ||
| 42163370 | Outcome of Board Meeting | 2026-03-26 | English | ||
| 42178686 | Resignation | 2026-03-25 | English | ||
| 42179973 | Trading Window | 2026-03-25 | English | ||
| 42190231 | Press Release | 2026-03-25 | English | ||
| 42170276 | General Updates | 2026-03-11 | English | ||
| 42187987 | Shareholders meeting | 2026-03-07 | English | ||
| 42188107 | Shareholders meeting | 2026-03-07 | English | ||
| 42193993 | Press Release | 2026-02-21 | English | ||
| 42175686 | Record Date | 2026-02-18 | English | ||
| 42183715 | Copy of Newspaper Publication | 2026-02-17 | English | ||
| 42189888 | Press Release | 2026-02-17 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Genprex, Inc.
Clinical-stage gene therapy company developing therapies fo…
|
GNPX | US | Professional, scientific and te… |
|
Genxone Spolka Akcyjna
A biotechnology company specializing in Next Generation Seq…
|
GX1 | PL | Professional, scientific and te… |
|
GeoVax Labs, Inc.
Clinical-stage biotech developing vaccines and therapies fo…
|
GOVX | US | Professional, scientific and te… |
|
GH Research PLC
Develops mebufotenin-based therapies for psychiatric and ne…
|
GHRS | IE | Professional, scientific and te… |
|
GI Innovation Inc.
Researches and develops protein-based drugs for immuno-onco…
|
358570 | KR | Professional, scientific and te… |
|
Ginkgo Bioworks Holdings, Inc.
Operates a horizontal platform for cell programming and syn…
|
DNA | US | Professional, scientific and te… |
|
GRAIL, Inc.
A healthcare company developing blood tests for multi-cance…
|
GRAL | US | Professional, scientific and te… |
|
GT Biopharma, Inc.
Clinical-stage immuno-oncology company developing therapies…
|
GTBP | US | Professional, scientific and te… |
|
Guard Therapeutics International AB
Clinical-stage biotech developing therapies to prevent acut…
|
GUARD | SE | Professional, scientific and te… |
|
Gubra A/S
Biotech and CRO focused on peptide drugs for metabolic and …
|
GUBRA | DK | Professional, scientific and te… |
Take Solutions Ltd via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/60381/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=60381 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=60381 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=60381 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 60381}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Take Solutions Ltd (id: 60381)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.